Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 2877.

https://doi.org/10.1182/blood-2019-128021

Published: 2019

Journal Articles

FcmR Shapes BCR Signaling in IgM-Positive Leukemia

Alexandra da Palma Guerreiro, PhD, Cornelia Dorweiler, Ismini Halmer, Olaf Merkel, Elena Maria Hartmann, MD, Valeska Berg, PhD, Nina Reinart, Günter Fingerle-Rowson, MD PhD, Gero Knittel, MSc, Christian Pallasch, MD, Andreas Rosenwald, Christian Reinhardt, MD, Clemens-Martin Wendtner, Michael Hallek, MD, Lukas P. Frenzel, MD

Blood (2018) 132 (Supplement 1): 2620.

https://doi.org/10.1182/blood-2018-99-118352

Published: 2018

Journal Articles

RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group

Sven Estenfelder, MD, Ann-Kathrin Holland-Letz, Eugen Tausch, MD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 1738.

https://doi.org/10.1182/blood.V130.Suppl_1.1738.1738

Published: 2017

Journal Articles

Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)

Othman Al-Sawaf, MD, Alexandra Bazeos, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Anna Maria Fink, MD, Julia Von Tresckow, Paula Cramer, MD, Petra Langerbeins, MD, Nadine Kutsch, MD, Kathryn Humphrey, PhD, Günter Fingerle-Rowson, MD PhD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Valentin Goede, MD

Blood (2017) 130 (Supplement 1): 1740.

https://doi.org/10.1182/blood.V130.Suppl_1.1740.1740

Published: 2017

Journal Articles

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Eugen Tausch, MD, Sven Estenfelder, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 1708.

https://doi.org/10.1182/blood.V130.Suppl_1.1708.1708

Published: 2017

Journal Articles

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Christiane Pott, MD PhD, David Belada, MD PhD, Nathalie Danesi, PhD, Günter Fingerle-Rowson, MD PhD, John Gribben, MDDSc, Chris Harbron, MPhil, Eva Hoster, PhD, Brad S Kahl, MD, Kirsten Mundt, PhD, Catherine Sebban, MD, Laurie H Sehn, MD MPH, Bruce D. Cheson, MD

Blood (2015) 126 (23): 3978.

https://doi.org/10.1182/blood.V126.23.3978.3978

Published: 2015

Journal Articles

Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)

Ciara Louise Freeman, MRCP, MD, Franck Morschhauser, MD PhD, Laurie H. Sehn, MDMPH, Mark Dixon, Richard Houghton, Thierry Lamy, MD, Gunter Fingerle-Rowson, MD PhD, Elisabeth Wassner-Fritsch, Michael Hallek, MD, Gilles Salles, MD PhD, Guillaume Cartron, MD

Blood (2014) 124 (21): 4674.

https://doi.org/10.1182/blood.V124.21.4674.4674

Published: 2014

Journal Articles

Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset

Ciara Louise Freeman, MRCP, MD, Mark Dixon, Richard Houghton, Kathryn Humphrey, Gunter Fingerle-Rowson, MD PhD, Karl-Anton Kreuzer, MD, Anja Engelke, MD, Michael Hallek, MD, Valentin Goede, MD

Blood (2014) 124 (21): 3339.

https://doi.org/10.1182/blood.V124.21.3339.3339

Published: 2014

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

NARROW

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

FcmR Shapes BCR Signaling in IgM-Positive Leukemia

RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group

Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)

Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only